Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following the company's $94M initial public offering. Aardvark (NASDAQ:AARD) shares opened at $15.18 after being ...

Aardvark Wine Lounge, 304 Pine St., in Green Bay opened Jan. 6, 2017 and will officially close on Feb. 21, according to a ...

Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Aardvark Therapeutics Inc. made its public market debut Thursday, securing $94 million in its initial public offering (IPO).

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...